Management of newly diagnosed patient with intermediate-stage HCC

Target Audience

The educational design of this activity addresses the needs of hepatologists, medical oncologists, pathologists, and interventional radiologists involved in the treatment of hepatocellular carcinoma (HCC).

Program Overview 

This Phone-a-Friend™ activity module features an interventional radiologist and a medical oncologist with expertise in intermediate-stage hepatocellular carcinoma (HCC) discussing their strategies for selecting and implementing first-line treatment for a patient with newly diagnosed intermediate-stage HCC. 

Educational Objectives 

After completing this activity, the participant should be better able to:

• Individualize first-line treatment approaches for patients with intermediate-stage hepatocellular carcinoma (HCC), accounting for tumor-specific and patient-specific factors

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal. 

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Relevant Financial Relationships

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Zachary T. Berman, MD:

• Consulting Fees: AstraZeneca plc, Boston Scientific Corporation, Guerbet SA, Sirtex Medical Limited, TriSalus Life Sciences, Inc.

Richard S. Finn, MD:

• Consulting Fees: AstraZeneca plc, Bristol Myers Squibb Company, Eisai Inc., Merck & Co., Inc., Pfizer Inc., Roche/Genentech, CStone Pharmaceuticals, Zai Lab;
• Contracted Research: Bristol Myers Squibb Company, Eisai Inc., Merck & Co., Inc., Pfizer Inc., Roche/Genentech, Inc. 

The planners and managers at Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact Integritas Communications at info@exchangecme.com.